Table 1 Patient characteristics
From: Inhibition of effector B cells by ibrutinib in systemic sclerosis
SSc (n = 24) | |
|---|---|
Demographics | |
Age (years) | |
Median | 54 |
Range | 30–81 |
Sex | |
Female | 15 (63%) |
Male | 9 (38%) |
Disease characteristics | |
SSc subtype | |
Limited cutaneous SSc | 14 (58%) |
Diffuse cutaneous SSc | 10 (42%) |
Disease duration (years) | |
Median | 8 |
Range | 1.2–24 |
Modified Rodnan skin score | |
Median | 8 |
Range | 0–44 |
Autoantibodies | |
Antinuclear antibodies (ANA) | 20 (83%) |
Anti-Scl-70 antibodies | 12 (50%) |
Anticentromer antibodies (ACA) | 6 (25%) |
Pretreatment | |
Cyclophosphamide | 4 (17%) |
Mycophenolate mofetil | 2 (8%) |
Stem cell transplant (> 10 years before blood draw) | 2 (8%) |
Immunosuppressive therapy at time of blood draw | |
None | 18 (75%) |
Prednisolone | 2 (8%) |
Mycophenolate mofetil | 2 (8%) |
Methotrexate | 3 (13%) |